AVTX
Avalo Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-19/100
Last price
13.59
▼ 1.01 (6.92%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
14.60
Day high
14.58
Day low
13.23
Volume
955.58K
Market cap
$728.83M
P/E (TTM)
—
52W range
12.51 – 24.27
Trailing performance
Returnvs SPY
1W
-12.77%
-14.7%
1M
-29.33%
-30.5%
3M
-29.26%
-33.8%
6M
-14.64%
-32.8%
YTD
-25.17%
-39.4%
1Y
+1.42%
-15.0%
3Y
-53.20%
-135.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AVTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+218.49K
Net buying
Buy transactions
20
590.15K shares
Sell transactions
18
371.66K shares
Net transactions
+38
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
905.81K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 10, 26 | SULLIVAN CHRISTOPHER RYAN Chief Financial Officer |
CONVERSION | 10.19K | $81.89K | Direct |
| Sep 10, 26 | SULLIVAN CHRISTOPHER RYAN Chief Financial Officer |
SELL | 10.19K | $179.46K | Direct |
| Aug 28, 26 | DOYLE MITTIE Officer |
CONVERSION | 679 | $5.46K | Direct |
| Aug 28, 26 | DOYLE MITTIE Officer |
SELL | 679 | $13.58K | Direct |
| Aug 18, 26 | SULLIVAN CHRISTOPHER RYAN Chief Financial Officer |
CONVERSION | 71.85K | $709.90K | Direct |
| Aug 18, 26 | SULLIVAN CHRISTOPHER RYAN Chief Financial Officer |
SELL | 72.72K | $1.45M | Direct |
| Aug 17, 26 | DOYLE MITTIE Officer |
CONVERSION | 1.00K | $12.65K | Direct |
| Aug 17, 26 | DOYLE MITTIE Officer |
SELL | 1.00K | $20.00K | Direct |
| Aug 11, 26 | RILEY JENNIFER Officer |
SELL | 2.65K | $52.01K | Direct |
| Aug 10, 26 | DOYLE MITTIE Officer |
CONVERSION | 679 | $5.46K | Direct |
| Aug 10, 26 | DOYLE MITTIE Officer |
SELL | 679 | $13.58K | Direct |
| Jul 27, 26 | DOYLE MITTIE Officer |
CONVERSION | 1.00K | $12.65K | Direct |
| Jul 27, 26 | DOYLE MITTIE Officer |
SELL | 1.00K | $20.00K | Direct |
| Jun 30, 26 | DOYLE MITTIE Officer |
CONVERSION | 4.65K | $50.67K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALMENOFF JUNE SHERIE |
Director | 4.17K | Conversion of Exercise of derivative security |
DOYLE MITTIE |
Officer | 51.78K | Conversion of Exercise of derivative security |
GOLDMAN JONATHAN |
Director | 3.17K | Conversion of Exercise of derivative security |
KANTOFF AARON |
Director | 6.33K | Conversion of Exercise of derivative security |
KAPLAN GILLA |
Director | 6.33K | Conversion of Exercise of derivative security |
NEIL GARRY A. M.D. |
Chief Executive Officer | 190.31K | Stock Award(Grant) |
RILEY JENNIFER |
Officer | 37.04K | Sale |
SULLIVAN CHRISTOPHER RYAN |
Chief Financial Officer | 39.90K | Conversion of Exercise of derivative security |
TRUEX SAMANTHA |
Director | 6.33K | Conversion of Exercise of derivative security |
VARKI PAUL C. J.D. |
Officer | 27.93K | Stock Award(Grant) |
Fundamentals
Market cap$728.83M
Enterprise value$328.80M
Revenue (TTM)$59.00K
Gross profit$-47.89M
EBITDA$-91.25M
Net income$-100.33M
EPS (TTM)$-4.31
Free cash flow$-23.27M
Total cash$400.28M
Total debt$242.00K
Book value / share$8.48
Shares outstanding53.63M
Float40.11M
Short % of float24.14%
Dividend yield0.00%
Beta (5Y)0.70
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.02
PEG ratio—
Price / sales—
Price / book1.60
EV / revenue5,572.84
EV / EBITDA-3.60
Gross margin0.00%
Operating margin-154847.45%
Profit margin0.00%
Return on equity-36.27%
Return on assets-18.50%
Debt / equity0.05
Current ratio19.31
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $59.00K | $441.00K | $1.92M | $18.05M | -86.6% |
| Operating revenue | $59.00K | $441.00K | $1.92M | $18.05M | -86.6% |
| Cost of revenue | $0 | -$366.00K | $1.28M | $3.43M | +100.0% |
| Gross profit | $59.00K | $807.00K | $640.00K | $14.62M | -92.7% |
| Research & development | $50.08M | $24.44M | $13.78M | $31.31M | +105.0% |
| Selling, general & admin | $22.90M | $17.24M | $10.30M | $20.71M | +32.8% |
| Total operating expense | $72.98M | $41.68M | $24.08M | $52.06M | +75.1% |
| Operating income | -$72.92M | -$40.87M | -$23.44M | -$37.44M | -78.4% |
| Net interest income | $4.35M | $3.31M | -$3.42M | -$4.17M | +31.4% |
| Pre-tax income | -$78.09M | -$35.02M | -$31.53M | -$41.63M | -123.0% |
| Tax provision | $165.00K | $114.00K | $14.00K | $28.00K | +44.7% |
| Net income | -$78.26M | -$35.13M | -$31.54M | -$41.66M | -122.8% |
| Net income to common | -$78.26M | -$35.13M | -$31.54M | -$41.66M | -122.8% |
| Basic EPS | -5.84 | -7.94 | -113.58 | -1,063.20 | +26.4% |
| Diluted EPS | -5.84 | -20.91 | -113.58 | -1,063.20 | +72.1% |
| EBIT | -$72.92M | -$40.87M | -$23.44M | -$37.44M | -78.4% |
| EBITDA | -$72.58M | -$40.70M | -$23.29M | -$37.27M | -78.3% |
| Basic shares | 13.40M | 4.43M | 277.73K | 39.18K | +202.9% |
| Diluted shares | 13.40M | 7.50M | 277.73K | 39.18K | +78.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.86M | $134.55M | $7.42M | $13.17M | — | -88.2% |
| Cash & short-term investments | $98.34M | $134.55M | $7.42M | $13.17M | — | -26.9% |
| Accounts receivable | — | — | — | $0 | $1.06M | — |
| Inventory | — | — | $0 | $20.00K | $38.00K | — |
| Total current assets | $105.29M | $138.89M | $8.39M | $16.42M | — | -24.2% |
| Property, plant & equipment | $460.00K | $1.21M | $1.97M | $2.41M | — | -62.0% |
| Goodwill & intangibles | $10.50M | $10.50M | $10.50M | $14.41M | — | 0.0% |
| Total assets | $116.46M | $150.73M | $20.99M | $33.37M | — | -22.7% |
| Total current liabilities | $12.94M | $6.96M | $4.62M | $22.11M | — | +85.9% |
| Current debt | — | — | — | $5.93M | — | — |
| Long-term debt | — | — | — | $13.49M | $32.83M | — |
| Total debt | $392.00K | $568.00K | $537.00K | $19.95M | — | -31.0% |
| Total liabilities | $33.41M | $17.70M | $13.69M | $44.28M | — | +88.8% |
| Retained earnings | -$448.52M | -$370.26M | -$335.13M | -$303.82M | — | -21.1% |
| Shareholder equity | $83.05M | $133.03M | $7.30M | -$10.91M | — | -37.6% |
| Working capital | $92.35M | $131.93M | $3.78M | -$5.70M | — | -30.0% |
| Net tangible assets | $72.55M | $122.53M | -$3.20M | -$25.32M | — | -40.8% |
| Shares issued | 18.51M | 10.47M | 801.75K | 39.29K | — | +76.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$78.26M | -$35.13M | -$31.54M | -$41.66M | — | -122.8% |
| Depreciation & amortisation | $344.00K | $169.00K | $158.00K | $166.00K | — | +103.6% |
| Stock-based compensation | $13.62M | $5.85M | $3.48M | $7.55M | — | +132.8% |
| Change in working capital | $3.84M | -$4.71M | -$9.24M | -$60.00K | — | +181.6% |
| Operating cash flow | -$51.46M | -$49.06M | -$30.68M | -$26.75M | — | -4.9% |
| Capital expenditure | — | — | — | -$95.00K | -$113.00K | — |
| Investing cash flow | -$81.72M | $356.00K | -$133.00K | -$95.00K | — | -23,055.1% |
| Share buybacks | — | — | — | -$14.81M | — | — |
| Financing cash flow | $14.59M | $175.85M | $25.04M | -$14.70M | — | -91.7% |
| Free cash flow | -$51.46M | -$49.06M | -$30.68M | -$26.85M | — | -4.9% |
| End cash position | $16.11M | $134.70M | $7.55M | $13.32M | — | -88.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $59.00K | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $59.00K | $0 | $0 | — | — |
| Cost of revenue | — | — | $0 | $0 | $0 | $0 | — |
| Gross profit | — | — | $59.00K | $0 | $0 | $0 | — |
| Research & development | $23.42M | $14.05M | $13.27M | $13.62M | $14.07M | — | +66.7% |
| Selling, general & admin | $8.10M | $6.85M | $6.53M | $5.58M | $5.24M | — | +18.2% |
| Total operating expense | $31.52M | $20.90M | $19.80M | $19.20M | $19.32M | — | +50.8% |
| Operating income | -$31.52M | -$20.90M | -$19.74M | -$19.20M | -$19.32M | — | -50.8% |
| Net interest income | $2.76M | $803.00K | $984.00K | $1.12M | $1.10M | — | +243.8% |
| Pre-tax income | -$36.34M | -$19.62M | -$13.59M | -$30.61M | -$20.75M | — | -85.2% |
| Tax provision | $18.00K | $12.00K | $130.00K | $11.00K | $16.00K | — | +50.0% |
| Net income | -$36.36M | -$19.63M | -$13.72M | -$30.63M | -$20.77M | — | -85.2% |
| Net income to common | -$36.36M | -$19.63M | -$13.72M | -$30.63M | -$20.77M | — | -85.2% |
| Basic EPS | -0.83 | -0.98 | — | -2.19 | -1.92 | -1.25 | +15.3% |
| Diluted EPS | -0.83 | -0.98 | — | -2.19 | -1.92 | -1.25 | +15.3% |
| EBIT | -$31.52M | -$20.90M | -$19.74M | -$19.20M | -$19.32M | — | -50.8% |
| EBITDA | -$31.50M | -$20.88M | -$19.73M | -$19.14M | -$19.18M | — | -50.8% |
| Basic shares | 43.60M | 20.11M | — | 14.00M | 10.83M | 10.51M | +116.9% |
| Diluted shares | 43.60M | 20.11M | — | 14.00M | 10.83M | 10.51M | +116.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $85.38M | $24.99M | $15.86M | $26.96M | $42.29M | +241.7% |
| Cash & short-term investments | $400.28M | $81.99M | $98.34M | $111.62M | $113.26M | +388.2% |
| Total current assets | $407.93M | $88.83M | $105.29M | $113.85M | $115.19M | +359.3% |
| Property, plant & equipment | $288.00K | $375.00K | $460.00K | $542.00K | $686.00K | -23.2% |
| Goodwill & intangibles | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M | 0.0% |
| Total assets | $490.78M | $99.89M | $116.46M | $125.10M | $126.58M | +391.3% |
| Total current liabilities | $21.13M | $11.60M | $12.94M | $7.97M | $9.26M | +82.2% |
| Total debt | $242.00K | $328.00K | $392.00K | $555.00K | $679.00K | -26.2% |
| Total liabilities | $42.12M | $31.57M | $33.41M | $33.55M | $22.01M | +33.4% |
| Retained earnings | -$504.51M | -$468.15M | -$448.52M | -$434.80M | -$404.18M | -7.8% |
| Shareholder equity | $448.66M | $68.32M | $83.05M | $91.55M | $104.57M | +556.7% |
| Working capital | $386.80M | $77.23M | $92.35M | $105.87M | $105.93M | +400.9% |
| Net tangible assets | $438.16M | $57.82M | $72.55M | $81.05M | $94.07M | +657.8% |
| Shares issued | 52.90M | 24.64M | 18.51M | 17.83M | 10.84M | +114.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$36.36M | -$19.63M | -$13.72M | -$30.63M | -$20.77M | -85.2% |
| Depreciation & amortisation | $17.00K | $17.00K | $16.00K | $59.00K | $134.00K | 0.0% |
| Stock-based compensation | $5.30M | $3.58M | $4.51M | $3.15M | $2.72M | +48.4% |
| Change in working capital | $8.68M | -$1.08M | $176.00K | -$1.15M | $3.61M | +904.3% |
| Operating cash flow | -$19.99M | -$17.69M | -$14.25M | -$16.36M | -$11.39M | -13.0% |
| Investing cash flow | -$329.93M | $25.50M | $2.40M | -$13.26M | -$70.86M | -1,393.6% |
| Financing cash flow | $410.21M | $1.40M | $687.00K | $14.37M | -$469.00K | +29,221.6% |
| Free cash flow | -$19.99M | -$17.69M | -$14.25M | -$16.36M | -$11.39M | -13.0% |
| End cash position | $85.61M | $25.32M | $16.11M | $27.26M | $42.52M | +238.2% |
Options analytics
Put / call volume
0.01
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
-81.6% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
5.08K
Contracts, this expiry
Put volume
55
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
10.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.62 | -0.83 | -34.5% |
| Mar 2026 | -1.07 | -0.98 | +8.6% |
| Dec 2025 | -1.50 | -0.37 | +75.3% |
| Sep 2025 | -1.64 | -2.19 | -33.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.56 | 8 | $0 | 0.0% |
| Next quarter | -0.52 | 8 | $0 | -100.0% |
| Current year | -2.73 | 8 | $0 | -100.0% |
| Next year | -2.71 | 10 | $0 | 0.0% |
Analyst targets & ownership
Mean target$44.08
High target$60.00
Low target$30.00
Implied upside224.38%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy2 / 12
Hold0
Sell / Strong sell0 / 0
Held by insiders1.69%
Held by institutions133.73%
Institutions holding179
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
15.06
-9.77% from price
SMA 20
15.84
-14.23% from price
SMA 50
17.96
-24.35% from price
SMA 100
17.42
-21.97% from price
SMA 200
16.68
-18.55% from price
EMA 12
15.25
-10.86% from price
EMA 26
16.30
-16.61% from price
EMA 50
17.08
-20.42% from price
RSI (14)
27.3
Oversold
MACD (12,26,9)
-1.05
Hist -0.13
ATR (14)
0.89
6.56% of price
Realised vol 30D
52.2%
Annualised
Bollinger upper
17.82
20, 2σ
Bollinger lower
13.87
20, 2σ
50 / 200 cross
Golden
17.96 vs 16.68
Trend bias
Below 200
-18.55%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.17
More volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
52.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-44.3%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
0.89
6.56% of price
Beta (reported)
0.70
5Y monthly, from filing
Short interest
Shares short
12.93M
Prior 13.09M
Change vs prior
-1.3%
Shorts covering
% of float
24.14%
Heavily shorted
% of shares out
24.10%
Against total outstanding
Days to cover
14.3
Crowded exit
Float
40.11M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 7, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 6, 26 | Leerink Partners | INITIATED | — | Outperform |
| Jun 16, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 12, 26 | B of A Securities | INITIATED | — | Buy |
| May 14, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| May 14, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 14, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| May 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 11, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| May 6, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| May 6, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:240
Split dateDec 29, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-06
Offering Registrations
S-3 · 2026-07-17
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-06-08
Periodic Financial Reports
10-Q · 2026-05-13
Corporate Changes & Voting Matters
8-K · 2026-05-07
Headlines
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 8d ago
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
GlobeNewswire · 14d ago
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 33d ago
Avalo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire · 34d ago
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing
MT Newswires · 48d ago
Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?
Simply Wall St. · 57d ago
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
GlobeNewswire · 62d ago
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
GlobeNewswire · 77d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.